<code id='17A6D840BA'></code><style id='17A6D840BA'></style>
      • <acronym id='17A6D840BA'></acronym>
      <center id='17A6D840BA'><center id='17A6D840BA'><tfoot id='17A6D840BA'></tfoot></center><abbr id='17A6D840BA'><dir id='17A6D840BA'><tfoot id='17A6D840BA'></tfoot><noframes id='17A6D840BA'>
      • <optgroup id='17A6D840BA'><strike id='17A6D840BA'><sup id='17A6D840BA'></sup></strike><code id='17A6D840BA'></code></optgroup>
        5. <b id='17A6D840BA'><label id='17A6D840BA'><select id='17A6D840BA'><dt id='17A6D840BA'><span id='17A6D840BA'></span></dt></select></label></b><u id='17A6D840BA'></u>
          <i id='17A6D840BA'><strike id='17A6D840BA'><tt id='17A6D840BA'><pre id='17A6D840BA'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / knowledge / leisure time      
           
     
           
      
          leisure time 
           
      
           
      
           
       2025-09-30 21:53:46 
   
      
           
      
           
                        
          leisure time  
          
                                   
                 
                                      author：Wikipedia   
                                        
                                      
                                      Page View：3
                                  
                                    
          
                                   
          Novo Nordisk Denmark
          LISELOTTE SABROE/AFP/Getty Images
          A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.
          In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.
          advertisement
          Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          ReNAgade cuts staff seven months after raising $300 million
                                
                            
          Next article：  
                                      
                                          Hollywood unions extend contract negotiations for actors
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles